Skip to main content

Table 3 Medical treatment for prosthetic and joint infections

From: Management of prosthetic joint infections in France: a national audit to identify key situations requiring innovation and homogenization

  Q1C1 Q1C2 Q2C1 Q2C2 Q3C1 Q3C2
Post-operative treatment Pre-operative documentation YES NO YES YES NO YES
Bacteriological documentation MSSA MSSA SAMS E. faecalis MSSA S. agalactiae
Narrow-spectrum antibiotic 99% (36.25/36.5) NA NA 24% (12/50) NA 45% (14/31)
Broad-spectrum antibiotic 0% NA NA 43% (21.5/50) NA 52% (16/31)
Oral antibiotic Rifampicine + quinolones 70% (28/40) 92% (33.5/36.5) NA NA 90% (19/21) NA
Total antibiotic regimen after DAIR 3 weeks 6% (2/36) NA NA NA NA  
4 weeks 35% (12.5/36)  
6 weeks 53% (0.5/36) 26% (6/23.5)
8 weeks 1% (0.5/36  
3 months 3% (1/36) 68% (16/23.5)
Suspensive NA 4% (1/23.5)
  1. DAIR Debridement, Antibiotic and Implant Retention, MSSA Methicillin-susceptible Staphylococcus aureus, NA Not applicable